An analysis of nearly 9,000 clinical trials of cancer therapies conducted between 2007 and 2010 found the trials tend to be smaller and less robust than trials for therapies in other disease areas. The Duke University analysis was part of the FDA's Clinical Trials Transformation Initiative to improve the quality and efficiency of clinical trials. Oncology trials tended to be small, early-stage and nonrandomized, researchers reported in JAMA Internal Medicine.
Analysis finds oncology trials may lack rigor
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|